Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more

Conditions: Breast Carcinoma, Colorectal Carcinoma
Interventions: Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Smoking Cessation Intervention, Health Promotion and Education, Informational Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 224
States / cities: Kingman, Arizona • Fort Smith, Arkansas • St. Helena, California + 187 more

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Acute Migraine
Interventions: Elismetrep; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 113
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more

Conditions: Tuberculosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fullerton, California • Los Angeles, California • Orange, California + 17 more

Conditions: Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression
Interventions: CYB003, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 36 more

Conditions: Select Advanced Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rett Syndrome
Interventions: fenfluramine hydrochloride, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 5 more

Conditions: Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage (ICH)
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 63
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more

Recruiting clinical trials

Filter and sort this status page

Live official records

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

FITting Non-invasive Tests in Lynch Syndrome Surveillance

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

Sleep to Predict Recovery In Unconscious Patients With Acute Brain Injury

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus